In recent years, chimeric antigen receptor- and TCR-engineered T cells, immune checkpoint inhibitors (including CTLA-4 and PD-1/PD-L1 inhibitors), cancer vaccines, and oncolytic viruses which would reverse the signals from the TME have been investigated as potential therapies for ovarian cancer [67]. This evidence concerns the gene PDCD1 and ovarian cancer.